TAS-102 and Bevacizumab as second line chemotherapy for colorectal cancer. Phase 2 trial
- Conditions
- metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000022437
- Lead Sponsor
- Teikyo University Chiba Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Not provided
1)contraindications for TAS-102 and Bevacizumab 2)previously received chemotherapy with TAS-102 3)severe drug allergy 4)pregnant woman or Possibility of the pregnant woman. male patient who hoping partner's pregnancy. 5)patient who has important clinical complications (symptomatic unstable ischemic heart disease, arrhythmia, acute myocardial infarction within 6 months, liver cirrhosis, renal failure, active gastrointestinal ulcer, ileus, uncontrolled diabetes, uncontrolled hypertension, etc.) 6)other active malignancies 7)have pleural effusion and ascitic fluid with the treatment 8)Comorbidity or history of heart failure 9)gastrointestinal ulcer or bleeding 10)previous hemoptysis 11)Peritoneal metastases at image 12)Clinical or radiological evidence of CNS metastases 13)Current or previous (within the last 6 months) history of GI perforation 14)Patient with interstitial pneumonia or lung fibrosis confirmed in imaging study 15)ongoing treatment with anticoagulant 16)Synchronous or metachronous multiple malignancy within the last 5 year disease free interval 17)Under continuous steroid administration 18)decision of unsuitable for this study by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method Time to Treatment Failure, response rate , overall survival